Nurix Therapeutics showcases early data on two programs for autoimmune and inflammatory diseases, NX-5948 and GS-6791, at ACR Convergence 2024.

Fate Therapeutics Showcases FT522, an Off-the-Shelf, ADR-Equipped CAR NK Cell Candidate, at the 2024 ACR Convergence.

Allogene Therapeutics shares preclinical findings for ALLO-329, a dual CAR T targeting CD19 and CD70, aimed at treating autoimmune diseases.

Ustekinumab, also known by its brand name Stelara, is a groundbreaking drug targeting interleukin-12 (IL-12) and interleukin-23 (IL-23).

Lilly's tirzepatide lowered the chance of worsening heart failure events by 38% in adults who have HFpEF and obesity.

Plozasiran, a novel therapeutic agent, is a small interfering RNA (siRNA) developed by Silence Therapeutics.

AbelZeta showcases preliminary findings on C-CAR168 for autoimmune disease treatment at ACR Convergence 2024.

Sacituzumab govitecan-hziy, also known as Trodelvy, is an antibody-drug conjugate (ADC) developed by Immunomedics, now part of Gilead Sciences.

Rona Therapeutics showcased encouraging Phase 1 findings for RN0191, an innovative siRNA treatment aimed at PCSK9, during the 2024 AHA Scientific Sessions.

The global pain management market was valued at $79.4 billion in 2021 and is projected to grow to $120.7 billion by 2027, with a compound annual growth rate (CAGR) of 7.39%.

AbbVie has obtained approval from the European Commission for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer.

Pegaptanib, developed by EyeTech Pharmaceuticals and later acquired by OSI Pharmaceuticals, is a pegylated aptamer that targets VEGF.